Mupirocin cream is as effective as oral cephalexin in the treatment of secondarily infected wounds

Journal of Family Practice

Volumn 47, Issue 6, 1998, Pages 429-433

  Kraus, Stephen J ^a   Eron, Lawrence J ^b   Bottenfield, Gerald W ^c   Drehobl, Margaret A ^d   Bushnell, William D ^e   Cupo, Michael A ^e,f  

^a Dermatology Associates   (United States)

^b Kanuai Medical Clinic

^c R/D Clinical Research Inc   (United States)

^d Centre for Health Care   (United States)

^e SmithKline Beecham Pharmaceuticals   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Abrasion; Cephalexin; Laceration; Mupirocin; Wound infection

Indexed keywords

CEFALEXIN; PSEUDOMONIC ACID;

ABRASION; ADULT; ARTICLE; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LACERATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; WOUND INFECTION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CEPHALEXIN; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUPIROCIN; PATIENT ACCEPTANCE OF HEALTH CARE; WOUND INFECTION;

EID: 0032425859     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Ward A, Campoli-Richards DM. Mupirocin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986; 32:425-14.
2. Welsh O, Saenz C. Topical mupirocin compared with oral ampicillin in the treatment of primary and secondary skin infections. Curr Ther Res 1987; 41:114-20.
3. Dux PH, Fields L, Pollock D. 2% topical mupirocin versus systemic erythromycin and cloxacillin in primary and secondary skin infections. Curr Ther Res 1980; 40:933-40.
4. Gratton D. Topical mupirocin versus oral erythromycin in the treatment of primary and secondary skin infections. Int J Dermatol 1987; 26:472-3.
5. Brenneman DL. Use of mupirocin ointment in the treatment of secondarily infected dermatoses. J Am Acad Dermatol 1990; 22:886-92.
6. Layton MC, Patterson JE. Mupirocin resistance among consecutive isolates of oxacillin-resistant and borderline oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1994; 38:1664-7.
7. Chatfield CA, O'Neill WA, Cooke RPD, et al. Mupirocin-resistant staphylococcus aureus in a specialist school population. J Hosp Infect 1994; 26:273-8.
8. Cookson BD, Lacey RW, Noble WC, et al. Mupirocin-resistant Staphylococcus aureus. Lancet 1990; 335:1095-6.
9. Gu JW, Briones F, Fang W, et al. Susceptibility of 1,309 nasal isolates of staphylococcus aureus from hospital personnel in the United States to 21 antibiotics. 91st General Meeting of the American Society for Microbiology, Dallas, Tex. 1991:A-97. (Abstract.)